Upload
alan-rodgers
View
221
Download
0
Tags:
Embed Size (px)
Citation preview
Treatment strategies for metastatic prostate cancer
Oliver HakenbergDepartment of Urology, Rostock University
prostate cancer is hormone-dependentprostate cancer is hormone-dependent
LHRH = LHRH = lluteinising hormone releasing hormoneuteinising hormone releasing hormoneLH = LH = lluteinising hormoneuteinising hormoneACTH = ACTH = aadrenocorticotropal drenocorticotropal hhormone ormone
testosterone
pineal gland
cortisole adrenalandrogens
Prostata
testes
prolactine
adrenal glands
hypothalamus
LH
ACTH
LHRHestrogens
orchidectomy
antiandrogens
LHRHanalogues
antiandrogens
0 1 2 3 4 5 6 7 8 90
10
20
30
40
50
Pathologic fractures after orchidektomy
n=235
Daniell et al, J Urol 1997
orchidectomy
no orchidectomy
years
% cumulative incidence of osteoporotic fractures
Immediate androgen ablation
• permanent– advanced metastatic disease M+– locally advanced, if androgen ablation is the
only treatment option
• adjuvant/temporary– radical prostatectomy with positive nodes
(pN+)– adjuvant with radiotherapy in intermediate and
high risk disease
Early or delayed androgen ablation?
Messing et al, Lancet Oncology 2006
RPE pN+early vs observation/delayedrandomizedn= 98
Overall survival
Cancer-specific survival
androgen ablation
• ↓ gonadal testosterone• 10-30% serum androgens from other sources • Adrenal cortex: DHEA + androstendione →
transformed to testosterone in periphery (including prostate)
• progression after xx months → hormone resistant
hormone resistance?
• de novo intratumoral androgen synthesis in progressive CRPC
• → maintenance of intracellular andogen levels • → androgen receptor (AR) stimulation despite
low serume testosterone
• „castration-resistant prostate cancer“ = CRPC
Locke et al, Cancer Res 2008
3 new developments
• autologous vaccine sipuleucel-T (IMPACT)– mCRPC docetaxel-naive (85%)– improved OS vs placebo
• cabazitaxel (TROPIC)– mCRPC doxetaxel-refractory – improved OS vs mitoxantrone
• arbiraterone– hormonal principle in CPRC
Kantoff et al, N Engl J Med 2010De Bono et al, Lancet 2010
Arbirateroneinhibition of testosterone biosynthesis
• arbiraterone acetate inhibits– C17,20 lyase– 17 hydroxylase– Inhibition selective & irreversible
• adrenals, testes, prostate cancer cells • arbiraterone acetate: prodrug• good oral bioavailability• Development of resistance
Sonpavde et al, Eur Urol 2011
Attard et al, Cancer Res 2009
Study data: arbiraterone in CRPC
• phase I– chemotherapy-naive CRPC patients
• phase-II NCT 00474383– progression after docetaxel
• phase-III NCT 00638690– progression after docetaxel
• phase III NCT 00887198– asymptomatic, low metastatic load in
chemotherapy-naive patients
phase I
• n=21
• chemo-naive, CRPC– 12/21 with PSA↓>50% and > 3 months– of which in 6/12 PSA↓ > 90%– PR (RESIST) in 5/8 patients and ↓analgesic
medication– no grade grade 3/4 toxicity
Attard et al, J Clin Oncol 2008
phase II a
• chemotherapy-naive CRPC patients
• PSA↓> 50% in 70-80% of patients
• RESIST response 37.5%
• median time to PSA-rise 225 days
• dexamethasone at progression with arbiraterone: further PSA↓>50% in 33%
Attard et al, J Clin Oncol 2009
phase II b
• n= 47 docetaxele-pretreated CRPC
• PSA↓> 50% in 51% of patients
• 35 with RESIST– PR 17%– SD 66%
• 23% ECOG improvement
Reid et al, J Clin Oncol 2009
Reid et al, J Clin Oncol 2009
Reid et al, J Clin Oncol 2009
Phase II c
• docetaxele-pretreated CRPC
• better efficacy without ketoconazole pretreatment– 53% vs 33% PSA-response without/with– 31% vs 4% PSA↓>90% without/with
ketoconazole– median time to progression 198 vs 99 days
with/without ketoconazole
Danila et al, J Clin Oncol 2009
phase III (COU-AA-301)
• n=1195 docetaxel-refractory CRPC
• arbiraterone vs placebo 2:1 randomisation
• stratification– ECOG 0-1 vs 2– prior chemotherapy schedules 1 vs 2– pain score – type of progression: PSA vs XR
• OS 14.8 vs 10.4 months• TTP 10.2 vs 6.6 months• rPFS 5.6 vs 3.6 months• PSA RR 29.1% vs 5.5%• toxicity
– hyperhydration 2.3% vs 1.0%– hypokalaemia 3.8% vs 0.8%– hypertension 1.3% vs 0.3%– cardiopulmonary 4.1% vs 2.3%
phase III (COU-AA-301) 1.interim analysis 2010
De Bono et al, ESMO 2010
arbiraterone
• n=1195 docetaxel resistant
• 2:1 randomisation– arbiraterone 1000 mg + 5 mg prednisone
vs
– placebo + 5 mg prednisone
• overall survival– arbiraterone 14.8 months
– placebo 10.9 months
de Bono et al, N Engl J Med 2011
treatment options for metastatic prostate cancer
• hormonal – androgen ablation
• orchidectomy• LHRH-antagonists or –agonists• androgen blockers
– androgen conversion blocker• arbiraterone
• chemotherapy– docetaxel– cabazitaxel
• bisphosphonates• pain treatment• nuclear medical tretament: samarium, strontium• best supportive care
Prognosis of metastatic prostate cancer
• initial response to androgen ablation > 80%
• progression in 50-60% of patients within 2 years
• after that median survival 23-37 months
• 5 year survival rate with M+oss 20%
androgen antagonists
• steroidal– cyproterone acetate
• non-steroidal– bicalutamide– flutamide– nilutamide
pro
po
rtio
n w
ith
ou
t ev
ent
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 6 12 18 24 30 36 42 48 60time (months)
bicalutamide 150 mg + standard carePlacebo + standard care
54
reduction of the risk of PSA progression by 59 %
Kaplan-Meier curve of time to PSA progression
HR 0.41; 95% CI 0.38, 0.45; p<<0.0001
Early Prostate Cancer Program
natural course of prostate cancer after radical prostatectomy and PSA recurrence (n= 311)
150 5 10years
PSA recurrencedistant metastases
death of prostate cancer
Pound et al., JAMA 1999
Hormone-independent prostate cancer
hormone independent
hormonesensitive
hormone dependent
hormone withdrawal
hormone naive hormone independent
definition of castration-resistant prostate hormone-refractory prostate cancer (HRPC)
• serume testosteron at castration level
• secondary hormonal treatment without effect• ketoconazole
• estrogens
• rising PSA at 3 consecutive measurements at intervals of 1 week at leastt• with continued LHRH – blockade and after witrhdrawal of androgen blocker
• lowest PSA limit: 0.4 ng/ml
Chemotherapy for prostate cancer?
Reviews response rates
1985: (17 Studien) 6,5 % M. Eisenberger, J Clin Oncol 1985
1992: (26 Studien) 8,7 % Yagoda & Petrylak, Cancer 1993
P.Walsh 1995:„This is going to be an extremely short discussion. Not only does it fail to cure the cancer, it doesn’t even prolong survival to any significant degree, and its side effects only add to the unpleasantness of having prostate cancer.“
• phase III: mitoxantrone (12mg/m²) + prednisone (10mg/d) vs. prednisone (10mg/d)
– 161 patients. (80 M+P; 81 P)
• phase III: mitoxantrone (14mg/m²) + hydrocortisone (40mg/d) vs. hydrocortisone (40mg/d)
– 242 patients
results– improvement in pain– improvement in quality of life– duration of response 5-7 months– no influence on survival
chemotherapy for prostate cancer – mitoxantrone for HRPC?
Tannock et al. 1996Kantoff et al. 1999
mitoxantrone approved by FDA
as standard chemotherapy in
HRPC
docetaxel
• TAX 327
• SWOG 9916
• both studies showed overall survival advantage for docetaxel
Petrylak, N Engl J Med 2004Tannock, N Engl J Med 2004
20%
40%
60%
80%
100%
0 12 24 36 48months
D + EM + P
no. at
Risk
338 336
217235
median survival(months)
1816
HR: 0.80 (95% CI 0.67, 0.97), p = 0.01med. F/U: 1 J
docetaxel chemotherapyoverall survival SWOG 9916
no (n)died
Petrylak et al, N Engl J Med 2004
SWOG 99-16
Petrylak J NCI 2006
Survival in subgroupsdocetaxel 3 weekly vs mitoxantrone
0.2 0.4 0.6 0.8 1 1.2 1.4
Intent to Treat
age < 65
age ≥ 65
age ≥ 75
pain no
pain yes
KPS ≥ 80
KPS ≤ 70
hazard ratio in favour of
docetaxel mitoxantrone
Tannock et al, N Engl J Med 2004
Cochrane Reviewchemotherapy of HRPC
• n=6929 patients; 47 studies• investigated substances:
– EMP
– docetaxel
– 5-FU
– cyclophosphamide
– doxorubicine
– mitoxantrone
– vinorelbine
Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006
Cochrane Review
• PSA response (>50%):– EMP 48%– docetaxel 52%– 5-FU 20%– cyclophosphamide n.d.– doxorubicine 50% (CAVE: only 1
study!)
– mitoxantrone 33%– vinorelbine n.d.
Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006
• only DOC => overall survival ↑ (<2.5 months)
• pain ↓ DOC > Mit + Pred• quality of life ↑ DOC > Mit + Pred
results
authors‘ conclusion:
„At the present time this* probably represents the best chemotherapeutic regime available for men with HRPC“
*- docetaxel q3w
Shelley M, Harrison C et al. Cochrane Database Syst Rev 2006
secondary hormone manipulation or chemotherapy?
secondary hormone manipulation
chemotherapy
CALGB9583 SWOG 9916 TAX-327
AAW + Ketokonazol
EMP docetaxel
vs MP
DP q3w
vs DP q1w vs MP
n 260 770 1006
overall survival in better arm
16.7 months 17.5 months 18.9 months
overall survival in worse arm
15.3 months 15.6 months 16.5 months
Bellmunt, Eur Urol Suppl 2009
open questions
• when to start with chemotherapy?• should asymptomatic M+ patients be treated?• how long to continue treatment?• secondary treatment?• intermittent chemotherapy?• re-exposition?
Early vs late chemotherapy?• for
– benefit established for other entities (breast cancer, colorectal cancer)
– lower tumour mass– treatment prolongs survival
• against– toxicity vs unreliable response– early induction of chemotherapy-refractory state– outcome is not influenced since no difference in
survival between symptomatic vs asymptomatic patients (TAX327)
forms of HRPCindications for starting with chemotherapy
• only rising PSA
• asymptomatic, low metastatic load
• asymptomatic, large metastatic load
• symptomatic metastases
no indication PSA doubling time?
individual decisioninclusion in study?
yes
yes
Estimating the prognosis in CPRCPSA doubling time
• günstig– TAX 327: PSA-DT > 55 Tage – Oudard et al: PSA-DT > 45 Tage
Armstrong et al, Clin Cancer Res 2007Oudard et al, Ann Oncol 2007
Armstrong, A. J. et al. Clin Cancer Res 2007;13:6396-6403
nomographic estimation
rising PSA under chemotherapy…
• often initiial PSA flare-up
• no negative influence on survival, unless there are signs of clinical progression
=> minimum of 8 weeks treatment before deciding to discontinue !
Olbert Anticancer Drugs 2006
Copyright restrictions may apply.Thuret et al, Ann Oncol 2008
PSA-Flare with chemotherapy in patients with subsequent PSA response or stable disease
PSA values normalized to a starting point of 100 ng/ml
Chemotherapy until…
• best number of cycles unknown
• TAX 327: mean of 8 cycles
• but: chronic toxicity increases with no of cycles
• intermittend chemotherapy?
When to discontinue chemotherapy…?
• definite worsening of physical state• PSA doubling time < 3 Monate• slow PSA increase:
- discontinue if clinically progressive
Miller et al. Akt Urol 2006
First line chemotherapydocetaxel Mono (75mg/m² KO d1, q21d)
Second line chemotherapyoptions:
– docetaxel (M D) PR: 44-85%
– docetaxel weekly PR: 72%
– mitoxantrone (D M) PR: 6-15%
– satraplatin (SPARC)
– cabazitaxel
Cabazitaxel second lineoverall survival
de Bono et al, Lancet 2010
open label, randomized, n= 755CPRC patients with progression on docetaxelcabazitaxel 25 mg/m2 q3w + prednisone 10 mg p.o. dailyvsmitoxantrone 12 mg/m2 q3w i.v.+ prednisone 10 mg p.o. daily
mean survival overallCABA 15.1 monthsMITO 12.7 months
Cabazitaxel second lineprogression-free survival
de Bono et al, Lancet 2010
ketoconazole• 200 or 400 mg tid p.o. ketoconazole
• + hydrocortisone replacement doses 30-0-10 mg p.o.
• n= 114
• response depends on disease burden
Keizman et al, Prostate 2010
Beltran et al, Eur Urol 2011
Hypothetical calculationFuture prognosis of metastatic prostate cancer?
• initial response to androgen ablation > 80%• progression in 50-60% of patients within 2 years • after that median survival 23-37 months• + 4 months with docetaxel• + 4 months with cabazitaxel• + 4 months with arbiraterone
„This will buy you three months“
Rostock